摘要
目的探讨D-二聚体水平在乳腺癌进展中的应用价值。方法选取2017年7月-2019年7月收治的78例晚期乳腺癌患者作为研究对象,给予化疗、内分泌治疗、靶向治疗、放疗、局部手术及抗血管生成等联合治疗,按照RECIST疗效评价标准分为完全缓解CR(0例)、部分缓解PR(48例)、疾病稳定SD(15例)、疾病进展PD(15例)4个等级,观察78例晚期乳腺癌患者的D-二聚体水平与临床病理特征关系,且评估治疗前后的D-二聚体水平。结果78例晚期乳腺癌患者的血浆D-二聚体含量在病理类型、分子分型等资料比较中,差异无统计学意义(P>0.05);<55岁患者的血浆D-二聚体水平(0.43±0.12)mg/L低于≥55岁以上的患者,差异有统计学意义(t=9.047,P<0.05);单个器官转移患者的血浆D-二聚体水平(0.42±0.17)mg/L显著低于多个器官转移患者,差异有统计学意义(t=10.528,P<0.05);PS评分<2分的患者血浆D-二聚体水平(0.43±0.12)mg/L低于PS评分≥2分以上的患者,差异有统计学意义(t=9.136,P<0.05)。部分缓解治疗后的血浆D-二聚体水平为(0.036±0.01)mg/L,低于治疗前,差异有统计学意义(t=37.066,P<0.05);疾病稳定治疗后的血浆D-二聚体水平为(0.060±0.02)mg/L,与治疗前相比,差异无统计学意义(t=1.732,P>0.05);疾病进展治疗后的血浆D-二聚体水平为(0.442±0.04)mg/L,高于治疗前,差异有统计学意义(t=77.847,P<0.05)。结论D-二聚体水平在乳腺癌患者的病情进展中发挥重要作用,其中D-二聚体水平的上升表示病情进一步恶化,D-二聚体水平的下降表示治疗方法有效,因此检测患者的血浆D-二聚体水平十分必要,值得推广及应用。
Objective To investigate the application value of D-dimer level in the progression of breast cancer.Methods 78 patients with advanced breast cancer admitted from July 2017 to July 2019 were enrolled in the study.Chemotherapy,endocrine therapy,targeted therapy,radiotherapy,local surgery and anti-angiogenesis were combined according to RECIST evaluation criteria.Divided into complete remission CR(0 cases),partial remission PR(48 cases),disease stable SD(15 cases),disease progression PD(15 cases)4 grades,78 cases of advanced breast cancer patients D-dimer Levels were correlated with clinicopathological features and D-dimer levels before and after treatment were assessed.Results The plasma D-dimer content of 78 patients with advanced breast cancer had no statistically significant difference in pathological type and molecular typing(P>0.05).Plasma D-dimer level in patients<55 years old(0.43±0.12))mg/L is lower than≥55 years old,the difference was statistically significant(t=9.047,P<0.05);plasma D-dimer level(0.42±0.17)mg/L in patients with single organ metastasis is significantly lower than multiple organ metastases Patients(t=10.528,P<0.05);patients with PS score<2 points plasma D-dimer level(0.43±0.12)mg/L lower than PS score≥2 points and the difference was statistically significant(t=9.136,P<0.05).The plasma D-dimer level after partial remission treatment was(0.036±0.01)mg/L,which was lower than that before treatment(t=37.066,P<0.05);the plasma D-dimer level after stable treatment of the disease was(0.060±0.02)mg/L,no difference compared with before treatment,the difference was not statistically significant(t=1.732,P>0.05);plasma D-dimer level after disease progression treatment was(0.442±0.04)mg/L,higher than treatment before,the difference was statistically significant(t=77.847,P<0.05).Conclusion The level of D-dimer plays an important role in the progression of breast cancer patients.The increase of D-dimer level indicates that the disease is further deteriorated.The decrease of D-dimer level indicates
作者
许丽莉
XU Li-li(Department of Oncology,Nanjing Xuanwu Hospital,Nanjing,Jiangsu Province,210000 China)
出处
《系统医学》
2019年第24期124-126,共3页
Systems Medicine
关键词
D-二聚体
乳腺癌
进展
D-dimer
Breast cancer
Progression
